Beta Bionics (BBNX) CCO offloads 353 shares in Rule 10b5-1 sale

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 353 shares of common stock in an open-market transaction on March 4, 2026. The shares were sold at an average price of $11.57 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 13, 2025.

After this sale, Hopman directly owned 139,133 shares of Beta Bionics common stock. The filing characterizes the transaction as an open-market sale, and the trading plan structure indicates it was executed under a pre-established schedule rather than at the insider’s discretion on the trade date.

Insider Trade Summary

Net Seller: 353 shares ($4,084)

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 353 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	353	$11.57	$4K

Holdings After Transaction: Common Stock — 139,133 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		353	D	$11.57	139,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

	/s/ Stephen Feider, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BBNX report for Mark Hopman on this Form 4?

Beta Bionics reported that Chief Commercial Officer Mark Hopman sold 353 shares of common stock. The sale occurred on March 4, 2026 as an open-market transaction at an average price of $11.57 per share under a Rule 10b5-1 plan.

Was the BBNX insider sale by Mark Hopman pre-planned under a Rule 10b5-1 plan?

Yes. The Form 4 states the 353-share sale by Mark Hopman was executed under a Rule 10b5-1 trading plan. That plan was adopted on May 13, 2025, indicating the sale followed a pre-arranged schedule rather than a discretionary trade on the sale date.

How many Beta Bionics (BBNX) shares does Mark Hopman hold after this Form 4 sale?

Following the reported transaction, Chief Commercial Officer Mark Hopman directly owns 139,133 shares of Beta Bionics common stock. This figure reflects his holdings after selling 353 shares on March 4, 2026 in the open market under a Rule 10b5-1 plan.

What price did Mark Hopman receive per share in the BBNX Form 4 sale?

The Form 4 reports that the 353 shares of Beta Bionics common stock were sold at an average price of $11.57 per share. This pricing applies to the open-market transaction executed on March 4, 2026 under a previously adopted Rule 10b5-1 trading plan.

What role does Mark Hopman hold at Beta Bionics (BBNX) in this Form 4 filing?

In this Form 4, Mark Hopman is identified as the company’s Chief Commercial Officer. The filing discloses his open-market sale of 353 shares of Beta Bionics common stock and his remaining direct ownership of 139,133 shares after the transaction.